FindTrial
Sign In

ezetimibe/simvastatin

DRUG7 trials

Sponsors

Organon and Co, Pfizer, University of Oxford, University of Colorado, Denver, University of Maryland, Baltimore

Conditions

Cardiovascular DiseaseCoronary Heart DiseaseDiabetes MellitusDiabetic PolyneuropathyDyslipidemiaHypercholesterolemiaHyperlipidemiaMetabolic Syndrome

Phase 2

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes
CompletedNCT00477204
University of Colorado, DenverDyslipidemia, Type 1 Diabetes Mellitus
Start: 2007-05-31End: 2010-08-31Updated: 2020-11-10
Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy
CompletedNCT02129231
University of GuadalajaraDiabetic Polyneuropathy, Oxidative Stress
Start: 2012-02-29End: 2014-04-30Updated: 2014-05-06

Phase 3

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
CompletedNCT00202878
Organon and CoHypercholesterolemia, Myocardial Infarction
Start: 2005-10-17End: 2014-09-18Updated: 2024-06-18
A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
TerminatedNCT00267267
PfizerDyslipidemia, Hyperlipidemia
Start: 2006-01-31End: 2007-01-31Target: 1784Updated: 2007-12-10
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
CompletedNCT00461630
University of OxfordCardiovascular Disease, Coronary Heart Disease, Diabetes Mellitus +1
Start: 2007-01-31End: 2012-10-31Updated: 2014-02-28

Phase 4

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment
CompletedNCT00819403
University of Maryland, BaltimoreMetabolic Syndrome
Start: 2009-01-31End: 2011-11-30Updated: 2020-01-14
A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)
WithdrawnNCT01587235
Organon and CoDyslipidemia
Start: 2013-03-31End: 2014-05-31Updated: 2022-02-18

Related Papers

Improving polygenic risk score based drug response prediction using transfer learning.
2025-11-21
Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome
JAMA Cardiology2022-10-1910 citations
Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT
Journal of the American Heart Association2022-02-0316 citations
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
2021-10-0132 citations
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT.
2020-09-1510 citations
Investigating modifications to participant information materials to improve recruitment into a large randomized trial.
2019-12-056 citations
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
2019-08-2219 citations
Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older
JAMA Cardiology2019-07-17114 citations
Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes
JAMA Network Open2019-03-0119 citations
Medication Discontinuation in the IMPROVE-IT Trial
Circulation Cardiovascular Quality and Outcomes2019-01-0149 citations
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
2018-11-02101 citations
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
2018-05-2643 citations
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Circulation Genomic and Precision Medicine2018-02-0192 citations
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus
Circulation2017-12-20414 citations
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Journal of the American Heart Association2017-11-0171 citations
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Circulation2017-10-02133 citations
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome
Circulation Cardiovascular Quality and Outcomes2017-05-0111 citations
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
JAMA Cardiology2017-03-14198 citations
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
2017-02-01129 citations
Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs
Circulation Cardiovascular Quality and Outcomes2016-07-019 citations

8 more papers not shown